Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study

Background Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity. A need exists to characterize efficacy/safety of...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of neurology Vol. 269; no. 9; pp. 5093 - 5104
Main Authors:	Gold, Ralf, Piani-Meier, Daniela, Kappos, Ludwig, Bar-Or, Amit, Vermersch, Patrick, Giovannoni, Gavin, Fox, Robert J., Arnold, Douglas L., Benedict, Ralph H. B., Penner, Iris-Katharina, Rouyrre, Nicolas, Kilaru, Ajay, Karlsson, Göril, Ritter, Shannon, Dahlke, Frank, Hach, Thomas, Cree, Bruce A. C.
Format:	Journal Article
Language:	English
Published:	Berlin/Heidelberg Springer Berlin Heidelberg 01.09.2022 Springer Nature B.V
Subjects:	Azetidines - pharmacology Azetidines - therapeutic use Benzyl Compounds - pharmacology Benzyl Compounds - therapeutic use Cognition Disease Progression Gadolinium Humans Lesions Magnetic Resonance Imaging Medicine Medicine & Public Health Multiple sclerosis Multiple Sclerosis - drug therapy Multiple Sclerosis, Chronic Progressive - diagnostic imaging Multiple Sclerosis, Chronic Progressive - drug therapy Multiple Sclerosis, Relapsing-Remitting - drug therapy NCT NCT01665144 Neurology Neuroradiology Neurosciences Original Communication Placebos Sphingosine 1-phosphate EXPAND Active secondary progressive multiple sclerosis Disability progression Cognition Siponimod MRI
ISSN:	0340-5354, 1432-1459, 1432-1459
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!